Home Companies Catalysts Deep Dives
Vraylar cariprazine APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaNeurology
Launch2015-09-17
US LOE2029-01-01
Peak Sales Est$5000M
Formulations[{"id":"vraylar-po","doses":"1.5-6mg","route":"PO","setting":"OUTPATIENT","frequency":"Once daily","
Companies
ABBV (ORIGINATOR)100%
Mechanism: D3/D2 partial agonist
Expert: Dopamine D3-preferring partial agonist with D2 partial agonism, providing balanced dopaminergic modulation in schizophrenia/bipolar.
Everyday: Balances dopamine activity in the brain to treat psychiatric conditions.
Targets: ["D3","D2"]
Revenue History
PeriodRevenue ($M)
2024$3,269M
2025$3,621M
Q4 2025$965M
Programs (2)
IndicationStageKey StudyRegional Status
BD-IAPPROVEDRGH-MD-05/06[{"stage":"APPROVED","region":"US","approval_date":"2015-09-17"}]
SCZAPPROVEDRGH-MD-03/04[{"stage":"APPROVED","region":"US","approval_date":"2015-09-17"}]
Notes
Dopamine D3-preferring atypical antipsychotic. Approved for schizophrenia and bipolar I. 2025 revenue $3.6B (+11% YoY). Differentiated efficacy/tolerability profile.
Data from Supabase · Updated 2026-03-24